MBNL1 and myotonic dystrophy type 1: While the second molecule is effective in reversing DM1-associated splicing alterations, the first molecule that targets MBNL1 causes the dysregulation of alternative splicing, suggesting that MBNL1 is not a suitable therapeutic target for the treatment of DM1 [156].